Top Injectable Manufacturer in Armenia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 6 days ago
- 10 min read
Last Updated: September 2, 2026
TL;DR: Armenia is the first market in this series where the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — has to be answered twice, once nationally and once for the Eurasian Economic Union. Nationally, the simplified 31-day route under the Law on Medicines is keyed to products registered by a member country of the ICH or PIC/S, or prequalified by the WHO. India's CDSCO is an ICH observer rather than a member and appears on no PIC/S list, so on the literal text an Indian-only registration does not qualify; whether the Armenian agency treats observers more generously is something we could not verify and will not guess. The larger fact is that Armenia is an EAEU member, and the union's registration rules closed the national route to new applications on 1 July 2021, so a new injectable enters through the EAEU mutual-recognition or decentralised procedure, in Russian, with an EAEU GMP inspection of the Gujarat site to plan for. The commercial gate is different again: out-of-pocket spending is 80.5% of health expenditure, the highest in the WHO European Region, which makes Armenia a pharmacy-shelf market rather than a tender market.
Key Takeaways
The national reliance list is defined by organisation, not by country. Government Decision N 172-A, as amended on 18 September 2025, names the ICH and PIC/S as the organisations whose member countries' registrations unlock the simplified procedure, alongside WHO prequalification. CDSCO is an ICH observer and is on none of the four PIC/S lists. Whether an observer counts as a member is unverified either way; a WHO-prequalified product qualifies regardless of origin.
The EAEU procedure is now the front door. EEC Council Decision No. 78 ended new national-route applications on 1 July 2021 and national authorisations on 31 December 2025 unless an alignment application had been filed. New products go through the mutual-recognition or decentralised procedure; the reference state has 210 calendar days, Armenia can be that reference state, and it issues EAEU GMP certificates.
A foreign company can hold the authorisation, but not alone. Neither the national law nor Decision 78 requires the holder to be resident, but the holder's representative must be a legal entity registered in a member state, the Russian-language SmPC, leaflet and mock-ups are mandatory with Armenian alongside, and only holders of an Armenian wholesale licence obtain import certificates, so a local importer sits at the supply end whatever the registration says.
The commercial gate is the pharmacy counter, not the tender. Out-of-pocket payments were 80.5% of current health expenditure in 2023 on World Bank data, and the WHO's 2024 health-system review describes a largely unregulated pharmaceutical market with reference pricing on the statute book only for reimbursed medicines. Distribution reach and price positioning matter more here than a procurement strategy.
Introduction: Why Armenia Demands a Premium Injectable Manufacturer in Armenia
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? In Armenia the honest answer takes two layers. The national Law on Medicines HO-86-N, in article 16(3) as amended on 11 April 2024, provides a simplified procedure — 31 calendar days in total, with no laboratory testing — for medicines already registered or assessed by the competent authority of a member country of the international professional organisations the Government designates, or prequalified by the World Health Organization. The designating instrument is Government Decision N 172-A of 23 February 2017, and since its amendment of 18 September 2025 those organisations are the ICH and PIC/S. India's CDSCO is an ICH observer, not a member, and it appears on none of the PIC/S lists of members, applicants, pre-applicants or former pre-applicants. Read literally, an Indian registration alone does not open the simplified route. Whether the Scientific Centre of Drug and Medical Technology Expertise treats observer status as sufficient we could not establish, and we will not resolve that ambiguity in either direction.
The second layer matters more in practice. Armenia is a member of the Eurasian Economic Union, and under EEC Council Decision No. 78 of 3 November 2016 the option to register under national law was available only until 1 July 2021. National authorisations issued before then remained valid at most until 31 December 2025 unless an application to align the dossier with union rules had been filed in a reference state, in which case the grace runs for up to three years there and two years in each recognising state. Armenia implemented that via Ministry of Health Order 3785-A of 24 June 2025 — an order we could locate but not read, since it exists only as a scanned image. The practical consequence for a new sterile injectable is unambiguous: it enters through the EAEU mutual-recognition or decentralised procedure, and the national simplified route, whatever the statute still says, is not the road a new applicant should plan around. For a buyer that changes what a premium injectable manufacturer in Armenia has to be: a partner fluent in the EAEU dossier and GMP regime, not just in CTD.
What Sets a World-Class Injectable Manufacturer in Armenia Apart
Start with the dossier format, because it is one of the few settled questions. The EAEU registration rules use a common technical document structure with a union-specific Module 1; SCDMTE publishes the EAEU application form and CTD guidance on its own site. The draft summary of product characteristics, patient leaflet and packaging mock-ups must be in Russian under Decision 78, and Armenia additionally requires Armenian-language product information under article 16(18) of the amended national law, so a serious supplier plans for two language versions from the outset. Whether Modules 2 to 5 are accepted in English in Armenian practice is not something we verified, so budget for translation until told otherwise. Timelines are statutory: the reference state's registration and expertise may not exceed 210 calendar days, the decentralised procedure runs 210 days from the last application, and a recognising state's expertise is capped at 50 working days. Fees we do not state, because the current Armenian fee decree and the EAEU-procedure tariffs were not retrievable and any figure we quoted would be a guess.
The GMP question is where an Indian site should be most clear-eyed. The union rules expect an EAEU GMP certificate. Where the applicant does not hold one, paragraph 30 of Decision 78 lets it file instead a home-country GMP certificate, the most recent inspection report not older than three years, a three-year history of inspections and complaints, a site master file and — the load-bearing item — written consent to a pharmaceutical inspection for compliance with EAEU GMP. The site is then placed on the reference state's inspection plan, and the reference state decides on an unscheduled inspection for any finished-product site not previously inspected by a member-state authority. Because India is on no PIC/S list, there is no shortcut around this, and a manufacturer who presents a WHO-GMP certificate as if it closes the GMP question is misreading the rules. Armenia itself issues EAEU GMP certificates and maintains a public list of them, so the inspection may well be Armenian rather than Russian — a useful fact for planning, not a waiver.
Quality Systems Behind Every Injectable Supplied to Armenia
For a sterile injectable, an EAEU GMP inspection of an ISO Class 5 filling line will be a real inspection, and the documentation must be ready before consent is given, not after. That means aseptic process simulation records, environmental monitoring trends, container-closure integrity data, sterility and bacterial endotoxin testing by LAL, and validated HPLC and GC methods with the impurity profiles and ICH Q1A stability data that underpin the shelf life claimed in the dossier. It also means a site master file written to the EAEU's expectations rather than recycled from another market. Post-registration, the amended Armenian law requires the holder to run a GVP-compliant pharmacovigilance system with a qualified person, and where that person sits outside Armenia, a locally responsible pharmacovigilance contact as well.
Two further points are easy to miss. Under article 21 of the amended law only holders of an Armenian wholesale licence obtain import certificates, and the importer must perform local batch release through a responsible person and relabel if the pack language differs — so the supply chain needs a licensed Armenian partner even when a foreign company holds the registration. And the Armenian pharmacopoeia list is set by Decree N 716-N of 2017, whose contents we did not read; we therefore do not assert whether the Indian Pharmacopoeia is recognised, and a supplier should specify to Ph. Eur., USP or BP monographs where a choice exists. On the WHO side, Armenia does not appear on the August 2026 list of authorities operating at maturity level 3 or 4; that establishes only that it is not listed, not what its benchmarked level is.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Armenia for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, maintain the analytical package — HPLC, GC, LAL, Karl Fischer, ICH Q1A/Q1B stability — that an inspector expects to see behind every batch record, and we are candid about what a given market's rules actually require. For Armenia that means we plan the EAEU route from the beginning: a paragraph 30 GMP package with consent to inspection, Russian and Armenian product information, an EAEU-resident representative for the holder, and a licensed Armenian importer for batch release. It also means we say plainly that, absent WHO prequalification, the national simplified route is not something we would build a timeline around.
The bilateral context is encouraging without being decisive. India's Ministry of External Affairs lists pharmaceuticals as India's fifth-largest export item to Armenia, and a memorandum of understanding between CDSCO and SCDMTE on cooperation in medical-product regulation was reported signed in New Delhi on 11 March 2025. We have seen only press accounts of that instrument, so we do not describe it as a recognition or mutual-recognition agreement; on the evidence available it is a cooperation framework. Trade in medicines is modest and the two sides' figures differ: India reports HS 30 exports to Armenia of about USD 2.57 million in 2023, USD 5.50 million in 2024 and USD 2.82 million in 2025, while Armenia reports imports from India of USD 3.95 million, USD 4.30 million and USD 4.15 million over the same years. We give both series rather than an average.
Where the money actually is: Armenia's population is about 3.09 million with gross national income per capita of USD 9,020 in 2025, current health expenditure of roughly USD 767 per person and 9.3% of GDP in 2023, and life expectancy of 78.3 years. The figure that shapes strategy is that out-of-pocket payments were 80.5% of current health expenditure in 2023, with the WHO's 2024 review noting that the largest share of that money goes on outpatient medicines. The State Health Agency buys centrally for state programmes through e-procurement, and a universal health insurance scheme backed by a USD 110 million World Bank loan is reported to launch from 2026 with external reference pricing for essential medicines — a development to watch, not yet a rule to plan around. Today, price positioning at the pharmacy counter and the reach of the licensed importer determine volume. Tuberculosis burden is low, with WHO estimating incidence at 19 per 100,000 in 2024 and 42 laboratory-confirmed rifampicin-resistant cases, so the injectable demand is the general hospital formulary rather than a single programme.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Armenia's list of recognised regulatory authorities?
The list is defined by organisation rather than by country. Government Decision N 172-A, as amended on 18 September 2025, names the ICH and PIC/S; a product registered by a member country of either, or prequalified by the WHO, is eligible for the 31-day simplified procedure under article 16(3) of the Law on Medicines. CDSCO is an ICH observer, not a member, and is on none of the PIC/S lists. On the literal text an Indian-only registration does not qualify. Whether SCDMTE accepts observer status in practice is unverified, and we will not claim it does or does not. A WHO-prequalified product qualifies whatever its origin.
Can we still register nationally in Armenia, or must we use the EAEU procedure?
Under EEC Council Decision No. 78, registration by choice under national law was available only until 1 July 2021, and national authorisations expired on 31 December 2025 unless an alignment application had been filed. New applications therefore follow the EAEU mutual-recognition or decentralised procedure. The Armenian statute still describes the national simplified route, and we found no 2026 evidence of SCDMTE accepting new applications under it; plan for the EAEU route.
Will Farbe Firma's WHO-GMP certificate be accepted, or will the Gujarat site be inspected?
Expect an inspection. The EAEU rules require an EAEU GMP certificate; without one, paragraph 30 of Decision 78 allows an alternative package — home-country GMP certificate, last inspection report, three-year inspection and complaints history, site master file and consent to an EAEU GMP inspection — after which the site goes onto the reference state's inspection plan. Because India is on no PIC/S list there is no waiver. Armenia issues EAEU GMP certificates itself, so the inspection may be Armenian.
Do we need a local company in Armenia to hold the registration?
Not to hold it. Article 16(9) of the national law allows the manufacturer or another responsible legal entity to be the applicant, and Decision 78 does not impose residency on the holder. But the holder's representative must be a legal entity registered in an EAEU member state, a locally responsible pharmacovigilance person is needed if the qualified person sits abroad, and only Armenian wholesale-licence holders receive import certificates and perform batch release. A local importer is therefore structurally necessary.
Is Armenia a tender market or a private market?
Overwhelmingly private. Out-of-pocket spending was 80.5% of current health expenditure in 2023, the highest share in the WHO European Region, and the WHO's 2024 review describes a largely unregulated pharmaceutical market. The Ministry of Health and State Health Agency buy centrally for state programmes, and the procurement law is reported to treat foreign bidders equally, but the volume sits at the pharmacy counter. Reference pricing exists in law for reimbursed medicines only; whether its reference-country list has been adopted we could not verify.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments